azathioprine
DISEASE INTERVENTION COMPARISON RESULTS
Arthritis Rheum. 2002 Aug;46(8):2121-31 Randomized Controlled Trial, Multicenter Study
IN lupus, systemic, with renal involvement, proliferative nephritis The Use of
low-dose IV cyclophosphamide (cumulative dose 3 gm), followed by azathioprine
As Treatment, Acute
Is equal Than
high-dose IV cyclophosphamide, followed by azathioprine
To reduce treatment failure at 40 months: 16% low-dose VS 20% high-dose (p NS). Renal remission achieved in 71% low-dose and 54% high-dose (p NS).
Cochrane Database Syst Rev. 2007 Oct 17;(4):CD003982 Systematic Review, Cochrane Review
IN multiple sclerosis The Use of
azathioprine
As Treatment, Chronic
Is better Than
placebo
To reduce, at 1 to 3 years, the number of patients who had relapses (relative risk reduction=20%) and who progresssed
N Engl J Med. 2012 May 24;366(21):1968-77 Randomized Controlled Trial, Multicenter Study
IN pulmonary fibrosis, idiopathic The Use of
a combination of prednisone, azathioprine, and N-acetylcysteine
As Treatment, Chronic
Is worse Than
placebo
To modify the outcomes : combination-therapy group, as compared with the placebo group, had an increased rate of death (8 vs. 1%) and hospitalization (23 vs. 7%)
Clin J Am Soc Nephrol. 2014 Jun 26. pii: CJN.00100114. [Epub ahead of print] Randomized Controlled Trial, Multicenter Study
IN vasculitis, ANCA-associated, involving the kidneys or another vital organ The Use of
switch from cyclophosphamide to azathioprine after 3-6 months
As Treatment, Chronic
Is worse Than
long-term Tt with cyclophosphamide for 12 months
To it increased the risk of relapse (HR 1.63, 44% all patients), and end-stage kidney disease (1.76, 9% all patients). No differences in mortality (HR 0.75, 15% all patients)
N Engl J Med. 2008 Dec 25;359(26):2790-803 Randomized Controlled Trial, Multicenter Study
IN vasculitis, ANCA-associated, Wegener,s granulomatosis, microscopic polyangiitis The Use of
azathioprine
As Treatment, Chronic
Is better Than
methotrexate
To prevent, at 29 months, relapses after remission (36.5% azat VS 33.3% methot) while avoiding adverse events requiring withdrawal (11% azat VS 19% methot)